Tanvex BioPharma, Inc. (6541.TW)
TWD 61.0
(2.35%)
TWD 61.0
(2.35%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.1 Billion TWD | -32.42% |
| 2022 | -1.58 Billion TWD | -5.97% |
| 2021 | -1.49 Billion TWD | 28.23% |
| 2020 | -2.08 Billion TWD | 7.66% |
| 2019 | -2.25 Billion TWD | -15.79% |
| 2018 | -1.95 Billion TWD | -39.01% |
| 2017 | -1.4 Billion TWD | -3.82% |
| 2016 | -1.35 Billion TWD | -62.45% |
| 2015 | -831.95 Million TWD | -78.95% |
| 2014 | -464.89 Million TWD | -54.27% |
| 2013 | -301.34 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -362.96 Million TWD | 13.99% |
| 2024 Q1 | -422.01 Million TWD | 14.33% |
| 2023 Q4 | -492.63 Million TWD | -0.29% |
| 2023 Q2 | -491.56 Million TWD | 17.41% |
| 2023 FY | -2.1 Billion TWD | -32.42% |
| 2023 Q3 | -491.2 Million TWD | 0.07% |
| 2023 Q1 | -595.17 Million TWD | -28.31% |
| 2022 Q2 | -413.44 Million TWD | -29.74% |
| 2022 Q4 | -463.86 Million TWD | -18.82% |
| 2022 Q3 | -390.39 Million TWD | 5.58% |
| 2022 Q1 | -318.68 Million TWD | 5.54% |
| 2022 FY | -1.58 Billion TWD | -5.97% |
| 2021 Q4 | -337.36 Million TWD | 13.18% |
| 2021 FY | -1.49 Billion TWD | 28.23% |
| 2021 Q2 | -459.73 Million TWD | -11.14% |
| 2021 Q1 | -413.65 Million TWD | 10.17% |
| 2021 Q3 | -388.6 Million TWD | 15.47% |
| 2020 Q4 | -460.51 Million TWD | -1.6% |
| 2020 Q1 | -623.83 Million TWD | -14.75% |
| 2020 Q2 | -561.97 Million TWD | 9.92% |
| 2020 Q3 | -453.25 Million TWD | 19.35% |
| 2020 FY | -2.08 Billion TWD | 7.66% |
| 2019 Q4 | -543.66 Million TWD | 22.28% |
| 2019 Q1 | -536.08 Million TWD | -13.35% |
| 2019 FY | -2.25 Billion TWD | -15.79% |
| 2019 Q2 | -548.91 Million TWD | -2.39% |
| 2019 Q3 | -699.49 Million TWD | -27.43% |
| 2018 Q3 | -484.9 Million TWD | 25.92% |
| 2018 FY | -1.95 Billion TWD | -39.01% |
| 2018 Q2 | -654.57 Million TWD | -93.58% |
| 2018 Q1 | -338.14 Million TWD | 12.02% |
| 2018 Q4 | -472.95 Million TWD | 2.46% |
| 2017 Q1 | -356.14 Million TWD | 24.82% |
| 2017 Q2 | -353.77 Million TWD | 0.66% |
| 2017 FY | -1.4 Billion TWD | -3.82% |
| 2017 Q3 | -308.89 Million TWD | 12.69% |
| 2017 Q4 | -384.35 Million TWD | -24.43% |
| 2016 FY | -1.35 Billion TWD | -62.45% |
| 2016 Q2 | -303.55 Million TWD | -15.75% |
| 2016 Q3 | -312.02 Million TWD | -2.79% |
| 2016 Q4 | -473.69 Million TWD | -51.81% |
| 2016 Q1 | -262.25 Million TWD | -5.98% |
| 2015 Q2 | -168.61 Million TWD | 0.0% |
| 2015 Q4 | -247.45 Million TWD | -0.08% |
| 2015 Q3 | -247.26 Million TWD | -46.64% |
| 2015 Q1 | -168.61 Million TWD | -27.2% |
| 2015 FY | -831.95 Million TWD | -78.95% |
| 2014 Q4 | -132.56 Million TWD | 0.0% |
| 2014 Q2 | -99.88 Million TWD | 0.0% |
| 2014 Q1 | -99.88 Million TWD | 0.0% |
| 2014 FY | -464.89 Million TWD | -54.27% |
| 2014 Q3 | -132.56 Million TWD | -32.72% |
| 2013 FY | -301.34 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Apex Biotechnology Corp. | 141.71 Million TWD | 1582.366% |
| Sinphar Pharmaceutical Co.,Ltd. | 286.05 Million TWD | 834.384% |
| Panion & Bf Biotech Inc. | 156.82 Million TWD | 1439.516% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 280.8 Million TWD | 848.106% |
| GenMont Biotech Incorporation | 6.98 Million TWD | 30162.25% |
| Abnova (Taiwan) Corporation | 47.19 Million TWD | 4551.307% |
| Adimmune Corporation | -722.74 Million TWD | -190.662% |
| Polaris Group | -1.84 Billion TWD | -13.736% |
| Energenesis Biomedical CO.,LTD. | -261.83 Million TWD | -702.312% |
| UnicoCell Biomed Co., Ltd. | -96.28 Million TWD | -2081.917% |
| PELL Bio-Med Technology Co. Ltd. | -411.24 Million TWD | -410.826% |